NDA 050278 · Avet
Achromycin V
Tetracycline Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1957
Oct 8, 1957
Approved uses
1
Original approval plus efficacy supplements
Registered trials
766
141 Phase 3, 52 recruiting
FAERS reports
779
507 serious, 212 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 18, 2025.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae. Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcalinfections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis. Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis ....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 8, 1957 Original approval
2 products under this application
- ACHROMYCIN V · TETRACYCLINE HYDROCHLORIDE 250MG · CAPSULE, ORAL · Prescription · TE AB
- ACHROMYCIN V · TETRACYCLINE HYDROCHLORIDE 500MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tetracycline" as an intervention, any sponsor and status, largest first.
- Sanitation, Water, and Instruction in Face-washing for Trachoma I/IIPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT02754583 · 47,605 participants · Start Dec 5, 2015 · Primary completion Dec 31, 2024
Drug: Azithromycin; Tetracycline · For: Trachoma
Sites: Addis Ababa, Ethiopia
- Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General PopulationPivotal-lookingActive, not recruiting
National Cancer Center, KoreaGovernment (non-federal)
NCT02112214 · 5,224 participants (planned) · Start Jun 2014 · Primary completion Dec 2029
Drug: 10-day bismuth-based quadruple therapy · For: Gastric Cancer; Helicobacter Pylori Infection
Sites: Busan, South Korea; Chuncheon, South Korea; Daegu, South Korea · 11 sites in all
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06943794 · 4,824 participants (planned) · Start Mar 30, 2026 · Primary completion May 1, 2030
Drug: recommendations for Hp eradication treatment · For: Gastric (Stomach) Cancer
Sites: Tongling, China
- Antibiotic Prophylaxis in High-Risk Arthroplasty PatientsPivotal-lookingEnrolling by invitation
Mayo ClinicAcademic, hospital or other
NCT04297592 · 4,618 participants (planned) · Start Jun 11, 2020 · Primary completion Jan 2027
Drug: Cephalexin; Doxycycline and 1 more · For: Infections Joint Prosthetic; Overweight or Obesity; MSSA Colonization and 6 more
Sites: Iowa City, Iowa; Rochester, Minnesota
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Azithromycin Reduction to Reach Elimination of TrachomaPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04185402 · 3,931 participants · Start May 29, 2021 · Primary completion Dec 18, 2024
Drug: Azithromycin · For: Trachoma
Sites: Niamey, Niger
- A Multi-center Study for Individual Treatment of Helicobacter Pylori InfectionPivotal-lookingStatus unknown
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT02689583 · 3,000 participants (planned) · Start Mar 2016 · Primary completion Mar 2017
Drug: Antibiotic selection based on the antibiotic susceptibility testing · For: Gastritis; Gastric Ulcer
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use226
- drug hypersensitivity154
- hypersensitivity125
- pneumonia106
- intentional product use issue104
- pain in extremity96
- vomiting95
- mobility decreased94
- arthralgia93
- neck pain91
- hepatitis88
- nausea88
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 11 |
| 2009 | 2 |
| 2010 | 9 |
| 2011 | 10 |
| 2012 | 15 |
| 2013 | 6 |
| 2014 | 5 |
| 2015 | 16 |
| 2016 | 34 |
| 2017 | 39 |
| 2018 | 26 |
| 2019 | 42 |
| 2020 | 74 |
| 2021 | 44 |
| 2022 | 55 |
| 2023 | 62 |
| 2024 | 162 |
| 2025 | 122 |
| 2026 | 36 |
Recalls
2 FDA enforcement reports for this application.
Mar 23, 2020 · Class I · Terminated
Failed Dissolution Specifications: Out of specification result during long term testing in Tetracycline HCl capsules.
Mar 23, 2020 · Class I · Terminated
Failed Dissolution Specifications: Out of specification result during long term testing in Tetracycline HCl capsules.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis.
Guan L, Beig M, Wang L, et al. · Ann Clin Microbiol Antimicrob 2024 · Systematic Review, Meta-Analysis
- Interventions for rosacea.
van Zuuren EJ, Graber MA, Hollis S, et al. · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Interventions for rosacea.
van Zuuren EJ, Graber MA, Hollis S, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Global Primary Antibiotic Resistance Rate of Helicobacter pylori in Recent 10ߙyears: A Systematic Review and Meta-Analysis.
Yu Y, Xue J, Lin F, et al. · Helicobacter 2024 · Systematic Review, Meta-Analysis
- Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis.
Hong TC, El-Omar EM, Kuo YT, et al. · Lancet Gastroenterol Hepatol 2024 · Meta-Analysis, Systematic Review
- Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis.
Salahi-Niri A, Nabavi-Rad A, Monaghan TM, et al. · BMC Med 2024 · Systematic Review, Meta-Analysis
Sponsor: Avet
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.